Antibiogram Pattern of Multidrug Resistance of Gram-negative Extended Betalactamase Isolates from Urine of Diabetic Patients

Abstract

Background: The rate of multidrug resistant bacteria is the most worrisome in the health setting because it often associates with nosocomial infection. Objectives: This present study aim at, evaluating the antibiotic pattern of multidrug resistance of Gram-negative extended betalactamase isolates from urine of diabetic patients. Methods: This is a cross sectional study carried out at Nnamdi Azikiwe University Teaching Hospital with a total of 110 diabetic patients and were recruited using convenient sample method. The patients were instructed on how to collect the mid-stream urine samples without contamination. The samples were cultured and characterized the isolates following standard bacteriological methods. The isolated bacteria were subjected to sensitivity test pattern using agar disc diffusion techniques. The multidrug resistant isolates were physically checked for the extended spectrum betalactamase production. Obtained data was subjected to these statistical tools; descriptive statistics, chi-square and pair-test using Statistical Package for the Social Science (SPSS version 26). Results: Out of 110 urine samples assessed for significant growth of bacteria, it was found that, 55(27%) were the Gram negative bacteria (GNB).The highest prevalence of isolates were E. coli 30(54.6%), followed by Klebsiella pneumonia 14 (25.5%), Pseudomonas aeruginosa 6 (10.9%), and Proteus species 5 (9.09%) respectively. The most occurrence of the MDR bacteria were found in Augmentin 46 (83.6%) as well as as Cefuroxime  43 (78.2%) respectively. The significant mean range of Augumentin and Cefixime resistant to ESBL producers were (0.53±1.2; p = 0.000) and (0.600 ± 0.974; p = 000) respectively. Conclusion: The study detected the high proportion of multi-drug resistant isolates and the most occurrence were found in E. coli and Klebsiella pneumoniae. Regular monitoring, conducting, supervising, or management of antibiotics and molecular biomarkers for drug resistance are paramount to curtail the rate of drug-resistant pathogens.